Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter. If you would like help with this search, please contact us at


For more information please click on the clinical trial number and you will be taken to the website.

Clinical Trial Phase Eligible Participant Official Title Drugs in Trial Location
NCT03522246IIINewly diagnosed stage III/IV epithelial ovarian cancer that responded to first-line platinum therapyATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)View DrugsArizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Michigan, Minnesota, Missouri, Nevada, New Jersey, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Dakota, Texas, Utah, Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cells
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitor
NCT02033616IINewly diagnosed stage III/IV ovarian cancerPhase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary TherapyView DrugsCalifornia
Drug(s) in Trial Other Drug Names Main Known Action
TAA-loaded autologous dendritic cell vaccineAnti-tumor immune response
NCT02166905IINY-ESO-1 or LAGE-1+ ovarian cancer with or without residual disease after treatmentA Phase I/IIb Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Combination With INCB024360 for Patients in Remission With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 AntigenView DrugsNew York
Drug(s) in Trial Other Drug Names Main Known Action
CDX-1401DEC-205/NY-ESO-1 fusion protein CDX-1401Immune response against cancer expressing NY-ESO-1
Epacadostat3-dioxygenase Inhibitor INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, INCB024360, IDO1 Inhibitor INCB024360Inhibits IDO to stimulate immune response
NCT03326193IINewly diagnosed stage IIIB-IV high grade serous or endometrioid ovarian cancer or other histologies if gBRCA positive (maintenance after platinum-based chemo+avastin)Phase 2, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Niraparib Combined With Bevacizumab as Maintenance Treatment in Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Following Front-line Platinum-based Chemotherapy With BevacizumabView DrugsAlabama, Alaska, California, Colorado, Florida, Kansas, Maryland, Michigan, Mississippi, Missouri, Nebraska, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Rhode Island, Tennessee, Texas, Washington
Drug(s) in Trial Other Drug Names Main Known Action
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonist
NiraparibMK4827, ZejulaPARP inhibitor
NCT03054909INewly diagnosed stage III/IV ovarian cancer (maintenance)QUILT-2.021: Randomized Study of Single Course of Intraperitoneal (IP) ALT-803 Followed by Subcutaneous (SQ) Maintenance ALT-803 Versus Subcutaneous (SQ) Maintenance ALT-803 Only After 1st Line Chemotherapy for Advanced Ovarian, Fallopian Tube, and Primary Peritoneal CancerView DrugsMinnesota
Drug(s) in Trial Other Drug Names Main Known Action
ALT-803Activates NK cells to stimulate immune response